ProKidney (NASDAQ: PROK) — Perfil da empresa, notícias e dados financeiros
ProKidney focuses on regenerative medicine for chronic kidney disease using its innovative REACT therapy.
ProKidney
ProKidney (NASDAQ:PROK) is a pioneer in regenerative medicine with a focus on kidney diseases. The company's main objective is to transform the treatment landscape for patients suffering from chronic kidney disease (CKD) and end-stage renal disease (ESRD) through innovative regenerative medicine therapies. ProKidney's leading project, REACT (Renal Autologous Cell Therapy), aims to delay or prevent the need for dialysis or transplantation by regenerating the patient's own kidney cells. By harnessing the body's natural healing process, ProKidney is dedicated to improving patients' quality of life and reducing the healthcare system's burden posed by kidney diseases.
Resumo
Operações
Produtos e/ou serviços de ProKidney
- Regenerative Medicine Solutions - Focused on developing therapies to treat chronic kidney disease through cellular and regenerative methods.
- Clinical Trials - Conducts advanced clinical trials for innovative kidney disease treatments, aiming at enhancing patient health.
- Stem Cell Research - Invests heavily in stem cell technology to pioneer breakthrough treatments for kidney regeneration.
- Patient Care Programs - Offers comprehensive care programs designed to support patients throughout their treatment journey.
- Educational Outreach - Provides resources and education to patients and healthcare professionals on kidney health.
- Technology Development - Continues to develop and refine technologies that support its core mission of treating chronic kidney diseases.
equipe executiva do ProKidney
- Bruce CulletonCEO & Director
- James CoulstonChief Financial Officer
- Todd C. GirolamoChief Legal Officer & Secretary
- Kenneth LockeChief Technical Officer
- Richard WilliamsChief Information Officer
- Carla PoulsonChief People Officer
- Joseph M. StavasSenior Vice President of Interventional Procedures
- Darin J. WeberChief Reg. Off, SVP and Head of Global Reg. Affairs, Quality Mgmt, Biometrics & Market Access
- Emily ButlerSenior VP of Biometric
- Gregory P. MadisonChief Commercial Officer
Principais indicadores financeiros
Resultados divulgados pela ProKidney , em USD.
- Cap. de mercado
- 606,8 mi
- Receita (TTM)
- 818 mil
- P/L
- —
- LPA (diluído, TTM)
- -0.6
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 893 mil | -165 mi | -69 mi | |
| 76 mil | -183,7 mi | -61,2 mi | |
| 0 | -151,5 mi | -35,5 mi | |
| 0 | -153 mi | -108 mi |